Elevated MCP1 and FABP4 in Early PCOS Pregnancy: Metabolic Markers Driven by Adiposity Rather Than Disease Status

MedXY Editorial Team•Mar 10, 2026•Diabetes & Endocrinology

Women with Polycystic Ovary Syndrome (PCOS) exhibit significantly higher concentrations of Monocyte Chemoattractant Protein-1 (MCP1) and Fatty Acid Binding Protein-4 (FABP4) in early pregnancy.
The elevation of these biomarkers is primarily mediated by maternal Body Mass Index (BMI), suggesting that adiposity is a more significant driver of inflammation than the PCOS diagnosis itself during gestation.
Despite the metabolic shifts, neither MCP1 nor FABP4 levels were found to interact with or predict adverse maternal or neonatal outcomes in this cohort.
The findings underscore the necessity of pre-conception weight optimization for women with PCOS to mitigate systemic inflammatory and metabolic stress.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Women with Polycystic Ovary Syndrome (PCOS) exhibit significantly higher concentrations of Monocyte Chemoattractant Protein-1 (MCP1) and Fatty Acid Binding Protein-4 (FABP4) in early pregnancy.
The elevation of these biomarkers is primarily mediated by maternal Body Mass Index (BMI), suggesting that adiposity is a more significant driver of inflammation than the PCOS diagnosis itself during gestation.
Despite the metabolic shifts, neither MCP1 nor FABP4 levels were found to interact with or predict adverse maternal or neonatal outcomes in this cohort.
The findings underscore the necessity of pre-conception weight optimization for women with PCOS to mitigate systemic inflammatory and metabolic stress.